Recombinant platelet factor-4: Began Phase I/II trial

Repligen Corp. (RGEN), Cambridge, Mass. Product: Recombinant platelet factor-4 (rPF4) Indication: Reverse heparin action after coronary artery bypass graft surgery Status: Began Phase I/II dose-escala...